

CURRICULUM VITAE

Gary Blick, MD
Medical and Research Director, CIRCLE Medical, LLC
153 East Avenue, Ste. 32
Norwalk, CT 06851
Tele: (203) 852-9525 / FAX: (203) 854-0371
EMAIL: BlickMD@CircleMedical.org

BIRTHDATE: November 18, 1955

EDUCATION: University of Florida, Gainesville FL, 1973-1974
Clark University, Worcester MA, 1974-1977, B.A.
University of Miami Medical School, Miami FL, 1979-1984, M.D.

PROFESSIONAL TRAINING:

1984-1985	Intern, Jackson Memorial Hospital, Miami FL
1985-1987	Junior and Senior Resident, Internal Medicine, Yale University School of Medicine Affiliate, Greenwich Hospital, Greenwich CT
1986	Acting Chief Resident, Greenwich Hospital, Greenwich CT

PRIOR HOSPITAL APPOINTMENTS:

1987-1991	Attending Physician, Dept of Medicine, Greenwich Hospital, Greenwich CT
1992-2001	Consulting Physician, HIV Specialist, Dept of Medicine, Greenwich Hospital, Greenwich CT
1992	Attending Physician, Dept of Medicine, St. Agnes Hospital/NY Medical College, White Plains NY
1994-2002	Attending Physician, Dept. of Medicine, Mt. Vernon Hospital, NY Medical College, Mt. Vernon NY

ACADEMIC APPOINTMENTS:

1992-2002	Assistant Professor of Medicine, Dept. Of Medicine, New York Medical College, Valhalla NY
-----------	--

PRIVATE PRACTICE:	1987-2002	Internal medicine, Primary Care HIV Specialist; Blick Medical Associates, Stamford CT
	2002-pres.	Medical and Research Director, Primary Care HIV/AIDS and Hepatitis Specialist; CIRCLE Medical, LLC, Norwalk CT

CERTIFICATION:	1984	Nat'l Board of Medical Examiners
	1987	Board Eligible, Internal Medicine
	2002-pres.	American Academy of HIV Medicine (AAHIVM)

LICENSURE:		Connecticut, Current #027524
------------	--	------------------------------

APPOINTMENTS

- Stewart B. McKinney Foundation, Fairfield, CT, Board of Directors, Medical Advisor, 1988-1992
- Greenwich Woods Health Care Center, Medical Director, 1988-1992
- Greenwich Hospital AIDS Task Force, Founder, Chairman, 1989-1991
- Southern New England Community Consortium, Greenwich CT, Medical Director, 1989-1995
- Greenwich AIDS Alliance, Greenwich, CT, Board of Directors, 1990-1999
- Greenwich AIDS Support Group Committee, Co-Chairman, 1990-1999
- Bread and Roses HIV Residence/Hospice, Medical Director, 1989-1998; Medical Advisor, 1998-2001
- AIDS Alliance of Greenwich, Greenwich, CT, Fund-Raising Committee, 1990-1991
- Peer Review Committee, Greenwich Hospital, 1990-1992
- Institutional Review Board, Greenwich Hospital, 1990-1992
- Stewart B. McKinney Foundation, Educational Scholarship Fund, Steering Committee, 1990-1991
- Stewart B. McKinney Foundation, Educational Scholarship Fund, Application Review Committee, 1990
- Triangle Community Center, Norwalk CT, Board of Directors, 1991-1992
- Data Safety and Monitoring Board (DSMB), reviewing Thymopentin (TP5) trial results, 1994-1996
- Institutional Review Board, Mt. Vernon Hospital, Mt. Vernon, NY, 1995-2002
- FDA Advisory Committee, Antiviral Drug Division, Guest Member, 1996
- Connecticut AIDS Drug Assistance Plan (CADAP), Hartford, CT, Advisory Committee, 1997-present
- Mid-Fairfield AIDS Project (MFAP), Norwalk, CT, Board of Directors, 2000-present
- Global Health Organization (GHO), Norwalk, CT, Founder, Director, 2001-present
- Millenium Biotechnology Inc., New York, NY, Medical Director, 2001-2002
- CT HIV/AIDS/STD Task Force, Founder, Director, 2003-present

WORK EXPERIENCE

- 1976-1977 Laboratory Technician, Dept. Of Genetics, Clark University, Worcester MA
- 1977-1979 Research Assistant, Dept. Of Dermatology and Biochemistry, University of Miami, Miami FL
- 1981-1982 Burn Technician, Burn Intensive Care Unit, Jackson Memorial Hospital, Miami FL
- 1982-1985 HIV Training , Immunsuppressive Unit, AIDS Program/Dr. Margaret Fischl, Jackson Memorial Hospital, Miami FL
- 1987-1988 House Physician, Lawrence Hospital, Bronxville NY
- 1986 Trainer/Lecturer, First Aid Conference, Greenwich Hospital, Greenwich CT
- 1986-1987 Emergency Room Physician, Greenwich Hospital, Greenwich CT
- 1986-1998 Guest Speaker, WGCH Talk Shows, Greenwich CT
- 1986-1987 Trainer/Lecturer, Advanced Cardiac Life Support Forum, Greenwich Hospital, Greenwich CT
- 1987-2002 Private Practice, Internal Medicine and Primary Care HIV Specialty, treating over 2000 patients with HIV Infection, Greenwich CT and Stamford, CT
- 1988-1991 Guest Speaker, WEBE 108-FM Radio Talk Show, "TAKE A STAND", Norwalk CT
- 1988-1999 Founder of HIV Positive, Women with HIV, and Family Members/Partners Support Groups, Greenwich CT
- 1988-1992 Medical Director, Greenwich Woods Health Care Center, Greenwich CT
- 1989 Guest Speaker, WNBC-TV, Waterbury CT, "Connecticut Newsmakers"
- 1990 Guest Speaker, WTIC-TV, Hartford CT, "Connecticut Now"
- 1989-1998 Medical Director, Bread and Roses, a non-profit HIV Residence and Hospice, Georgetown CT
- 1989-2001 Medical Advisor, Bread and Roses, Georgetown CT
- 1990 Medical Representative, New Haven, CT, Mayors AIDS Task Force, lobbying bill passed by CT State Senate Approving Medicaid to pay private insurance premiums for HIV-Infected individuals qualifying for State Welfare
- 1990-1998 Member, AIDS Alliance of Greenwich, Board of Directors, Greenwich CT
- 1991 Guest Speaker, News 12 TV, Norwalk CT, "Fairfield Exchange"
- 1991-1995 Medical Director, Southern New England Community Consortium, dedicated to the advancement of experimental and investigational therapies for people with HIV infection, Greenwich CT
- 1991-1994 Vice President, TETRAGON, non-profit organization of community-based physicians for development of investigational therapies for people with HIV infection, Greenwich CT
- 1991,1993 Guest, COMMUNITY FOCUS, Dr. Mark Gang, "State-of-the-Art Update on AIDS", CT Public TV
- 1991-2000 Guest, FAIRFIELD EXCHANGE, Ch I2-TV; TOPICS: McKinney Foundation, Protease Inhibitor/HIV Therapies And Future, PML Therapy with Cidofovir and Ara-C, Unusual Transmissions of HIV, AIDS in Africa
- 1992-1995 Editor/writer, OPTIONS HIV newsletter
- 1992 Guest, Dr. Stuart Berger Radio Talk Show, "Use of Nontraditional Therapies for HIV Infection"

- 1992 Guest, Dr. Stuart Berger Talk Show, Manhattan Cable-TV, "Use of Passive Immunotherapy, Plasmapheresis, and gp160 Vaccine in HIV-Infected Individuals"
- 1992 Protocol Development, wrote Phase II/III Trial of VaxSyn gp160 in HIV Infected Individuals, 16-center nationwide trial, 3300 patients, sponsored by Wyeth-Ayerst Pharmaceuticals
- 1994 Peer Reviewer, Journal of Infectious Diseases
- 1994 Feature Story, STEALS AND DEALS, CNBC, "HIV Misdiagnosis"
- 1994 Feature Story, NBC-TV Evening News, "Misdiagnosis"
- 1994,1995 Feature Story, Ch8-TV, FIRST LOOK, "Misdiagnosis"
- 1995 Feature Story, 60 MINUTES, CBS-TV, "HIV POSITIVE"
- 1995 Medical Expert, Lawsuit involving misdiagnosis and treatment of HIV-seronegative individual with HIV therapies, for the prosecution, case won/\$2.3M award, Washington DC
- 1995-2002 Institutional Review Board, Co-Chairman/Member, Mt. Vernon Hospital
- 1996 FDA Antiviral Advisory Committee, Antiviral Drug Division, Guest Member
- 1997-Pres. Connecticut AIDS Drug Assistance Plan (CADAP), Advisory Committee, Medical advisor
- 1997 Feature Story, 20/20, ABC-TV, "Euthanasia"
- 1998-1999 Protocol Development, "A Phase II Multi-Center Trial Using Low Flow, Extracorporeal Whole-Body Hyperthermia (EWBH) in HIV/AIDS Patients Resistant to Antiretroviral Therapies", for First Circle Medical, Inc., FDA-approved July 1999
- 1998 Medical Expert, Lawsuit involving misdiagnosis and treatment of HIV seronegative woman with HIV therapies, settled out of court, New Haven CT
- 2000-Pres. Board of Directors, Mid-Fairfield AIDS Project (MFAP), Norwalk CT, a non-profit organization meeting the medical and social needs of the HIV+ community
- 2001 Protocol Development, "A Phase I/II Study Using Intramuscular Oleander (Anvirzel) in HIV-Seropositive Patients with CD4>200 and Controlled Viremia", for Ozelle Pharmaceuticals, Inc. San Antonio, TX
- 2001 Protocol Development, "Resensitization and Salvage Treatment of HIV Infected Individuals Failing HAART by Ampligen Intervention", for Hemispherx Biopharma, Philadelphia PA, FDA-approved April 2001
- 2001 Protocol development, "A Pilot Study Evaluating the Effects of Immunocal[®] on Metabolic, Virological, and Immunological Parameters in HIV/AIDS Patients", for NuMedTech, Inc., California.
- 2001 Protocol Development, "A Pilot Study Evaluating the Effects of Resurgex[™] on Metabolic, Virological, and Immunological Parameters in HIV+ Patients", for Millenium Biotechnology, Inc., New Jersey
- 2001-2004 Medical Advisor, Millenium Biotechnology, Inc., New Jersey
- 2001-Pres. Founder, CEO and Director, Global HEALTH Organization, Inc., 501(c)3 non-profit organization to provide education, patient assistance, nutrition, and medical care for HIV, Hepatitis, and other health-related issues in developing countries and the USA, Norwalk CT
- 2001 Protocol Development, "A Phase I/II Study Evaluating the Safety and Efficacy of Subcutaneous PreTaylavr[®] Antibody Therapy in HIV/AIDS Patients, for ViraLabs Inc., Dallas TX, 2001-2

- 2002-Pres. Medical Director, CIRCLE Medical, LLC, The Comprehensive Immunology and Research Center for Life Extension, specializing in clinical research and specialty medical care for those infected with and affected by HIV/AIDS and Hepatitis
- 1990s-Pres. Medical Consultant: Abbott Pharmaceuticals, Boehringer-Ingelheim, Bristol Meyers Squibb, GlaxoSmithKline, Merck Pharmaceuticals, Serono, Gilead Sciences, Auxilium, Solvay
- 1990s-Pres. Medical Advisor: Abbott Pharmaceuticals, Bristol Meyers Squibb, GlaxoSmithKline, Serono, Gilead Sciences, Boehringer-Ingelheim, Solvay, Auxilium
- 2003-Pres. Founder/Director, CT HIV/AIDS/STD Task Force, organized to understand the latest epidemic of HIV and STDs in the CT MSM community and to create a model to reduce the transmission and incidence of HIV and STDs

LECTURES/PRESENTATIONS

- 1991 Lecture: "Therapeutic Uses of gpl60 Vaccine in HIV-Infected Individuals", Third Triennial Symposium on Antiviral Chemotherapy, San Francisco CA.
- 1991 Lecture: "HIV-1 gpl60 Vaccine and Passive Immunotherapy: Potential Therapeutic Uses In HIV Infection", NYU Medical Center, NY
- 1992 Lecture: "Alternative and Nontraditional Therapies in the Treatment of HIV Infection", Second Annual Clinical Care Options for HIV Infection, Phoenix, AZ
- 1992 Oral Presentation, VIII International Conference on AIDS, Amsterdam, Netherlands, "Phase I/II Trial Involving VaxSyn HIV-1 gpl60 vaccine in Individuals with HIV Infection"
- 1992 Oral Presentation, 3rd AIDS Vaccine Conference, Chantilly VA, "Phase 1/11 Trial Involving VaxSyn HIV-1 gpl60 in Individuals with HIV Infection: 18-Month Preliminary Observations"
- 1993 Lecture: "HIV in the 90's: State-of-the-Art Update", Connecticut Visiting Nurse's Association, Hartford CT
- 1993 Lecture: "HIV Infection: an Update", Continuing Medical Education Seminar for CT Emergency Medical Services, Greenwich CT
- 1994 Manuscript Presentation: "A Study of Passive Immunotherapy and Therapeutic Plasmapheresis in a Community-Based Setting", First International Conference on Passive Immunotherapy, Royal College of Physicians, London England
- 1994 Lecture: "Passive Immunotherapy and Therapeutic Plasmapheresis in a Community-Based Setting", HIV Immunotherapy Conference, NYU Medical Center, NY
- 1994 Lecture: "Passive Immunotherapy and Therapeutic Plasmapheresis in a Community-Based Setting", Conference on Passive Immunotherapy, Biltmore Hotel, Coral Gables FL
- 1994 Lecture: "HIV Infection: Chronic, Manageable, and Treatable", WCGLBG, Elmsford, NY
- 1997 Lecture: "State-of-the-Art HIV Therapies", Grand Rounds, Mt Vernon Hospital, NY
- 1997 Lecture: "Comprehensive Management of HIV Infection", Dinner meeting, Greenwich Hyatt, Greenwich CT
- 1997 Lecture: "Treatment of HIV Infection In 1997", Mid-Fairfield AIDS Project, Norwalk Library, Norwalk CT
- 1997 Lecture: "The Latest in HIV Therapy for the Pharmacist", CT Pharmacists Association, Stamford Marriott, Stamford CT
- 1998 Lecture: "Overview of HIV Treatments and Management in 1998 and the Future", Bridgeport Health Project, Bridgeport CT
- 1999 Lecture/Forum, Extracorporeal Whole-Body Hyperthermia for HIV/AIDS, 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon Portugal
- 1999 Lecture/Forum, Extracorporeal Whole-Body Hyperthermia for HIV/AIDS, Amsterdam, The Netherlands
- 2000 Keynote Lecture: "HIV/AIDS Outlook in the 21st Century", HIV/AIDS Expo, Norwalk, CT
- 2000 Lecture: "Safer Sex: Bare-Backing and Regression Back to the 80's", Westport, CT
- 2000 Lecture: "EWBH for the Treatment of Drug-Resistant HIV+ Patients", Utrecht, Netherlands
- 1999 Lecture: "EWBH: Past, Present, and Future", AIDS Project Hartford, Hartford, CT

- 1999 Workshop: "EWBH: Safety and Efficacy in HIV/AIDS Patients Resistant to HAART", 7th AMFAR Meeting on HIV/AIDS, San Francisco, CA.
- 2000 Keynote Lecture: "HIV/AIDS: 20 Years of a Global Crisis, How Far Have We Come, and Where Are We Going?", HIV/AIDS Business Expo, Norwalk, CT
- 2000 Lectures: "Trizivir and Hypersensitivity", Bronx NY and Mahopac NY
- 2001 Lecture: "Triple Nucleosides as Initial Therapy for the Treatment of HIV/AIDS", Bronx NY
- 2001 Lecture: "The Role of Androgenic and Anabolic Steroids in the Treatment of HIV/AIDS Patients", Westport CT
- 2001 Lecture: "Tenofovir: Its Role in Treatment of Salvage and ARV-Naïve HIV/AIDS Patients", Rye, NY
- 2002 Lecture: "Update: XIV International AIDS Conference, Barcelona Spain", Stamford CT
- 2002 Lecture: "Tenofovir: Update 2002", Norwalk, CT
- 2002 Oral Presentation, HIV DART 2002: Frontiers in Drug Development for Antiretroviral Therapies, Naples, FL, "A Phase IIB Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Poly I:Poly C₁₂U Against HIV During Structured Treatment Interruption (STI) of HAART"
- 2003 Guest Lecturer, Chinese CDC/Ministry of Health: "Global Overview HIV/AIDS 2003"; "8 Lessons Learned by HIV/AIDS Expert from 1987-2003"; "Phase II Results of EWBH as Salvage Therapy in HIV/AIDS Patients Resistant to HAART"
- 2003 Oral Presentations: 9th Annual Ampligen Clinical Investigator's Meeting, Hawk's Cay, FL: Interim Results of AMP 719 and AMP 720
- 2004 Oral Presentation, Provisions, New Haven, CT: "Metabolic Complications of HIV/AIDS"
- 2005 Oral Presentation, 3rd IAS Conference, Rio de Janeiro, Brazil, July 25, "Patient Zero: The Connecticut Source of the Multi-drug Resistant, Dual-Tropic Strain of HIV Found in NYC"
- 2005 Oral Presentation, ANAC, Wallingford, CT: "Newer Strategies for Salvage Therapy in HIV/AIDS"

FEATURE ARTICLES

Berger S. New AIDS Vaccines Encouraging. New York POST, Doctor's Orders, 1992;February 27:12.

Martin RP. Blick's Work Continues to Impact Lives. Metroline, 1992;October 29:16.

Lang J. HIV Positive: Dr. Blick Won't Accept AIDS as a Death Sentence, But Will the Medical Establishment Accept Dr. Blick? Hartford Courant, Northeast Magazine, 1993;March 7:6-16.

Brownworth V. Immunotherapy. Metroline. 1993;April 1:28-36.

Brownworth V. AIDS Vaccines: Hope or Hype? OUT, 1993;June/July:90-1.

Allen J. Misdiagnosis: The Charlene Riling Story. The New York Native. 1994;October 15-22.

Allen J. Life After AIDS: The Charlene Riling Story. IN Newsweekly, 1995;4(20):4-6.

Blick G. An Integrated Approach to CMV Retinitis Management. VISTIDE VIEWS, 1997;1:3-4.

RESEARCH/CLINICAL TRIALS EXPERIENCE

1. Phase I/II Trial of Intramuscular Immunization with VaxSyn gpl60 In HIV-Infected Individuals, 1990-1996, completed.
2. Phase I/II Trial of Intradermal Immunization with VaxSyn gpl60 in HIV-Infected Individuals, 1991-1993, completed.
3. Open Label Treatment IND/Compassionate Use/Expanded Access Protocols (24):
 - DDC, Roche, 1990-1992
 - DDC combination with AZT, Roche, 1991-1992
 - DDI, Bristol-Meyers, 1991-1993
 - GM-CSF, Schering, 1993-1994
 - Fluconazole, Pfizer, 1992-1994
 - Atovaquone, Burroughs-Wellcome, 1993-1994
 - D4T (Stavudine), Bristol-Meyers, 1994-1995
 - 3TC (Lamivudine), Glaxo-Wellcome, 1994-1996
 - Oral Ganciclovir, Syntex, 1995
 - Liposomal Amphotericin B (ABLIC), Vestar, 1995
 - Cidofovir, Gilead Sciences, 1995-1996
 - Intravenous Peptide T/Cidofovir for PML, Advanced Peptides/Gilead, 1996
 - IND: Cidofovir with Ara-C for PML, Gilead Sciences, 1996-7
 - Saquinavir, Roche, 1996
 - Delavirdine, Pharmacia-Upjohn, 1996-7
 - Nelfinavir, Agouron, 1997
 - DMP266/Sustiva, Dupont-Merck Pharmaceuticals, 1998
 - Adefovir/Preveon, Gilead Sciences, 1998
 - Agenerase, Glaxo-Wellcome, 1999
 - Kaletra (Lopinavir), Abbott Laboratories, 2000
 - Viread (tenofovir), Gilead Sciences, 1999-2001
 - T-20, Roche/Trimeris, 2002-3
 - Atazanavir, BMS, 2002-3
 - Tipranavir (Aptivus), BI, 2004-5
4. Phase I/II Trial of Passive Immunotherapy in Individuals with AIDS/ARC/or CD4+ <200 cells/mm³, 1990-1998, completed.
5. Phase I/II Double-Blind, Placebo-Controlled Efficacy Trial of Thymopentin (TP5) with AZT in HIV-Infected Individuals, CD4+ 200-500, July 1991-December 1992, completed.
6. Phase III Rollover Open-Label Trial of Thymopentin (TP5) with AZT in HIV-Infected Individuals, 1992-1996, completed.
7. Phase I/II Trial of Plasmapheresis in Healthy Asymptomatic HIV-Infected Individuals, 1990-1998, completed.
8. Double-Blind Study of Timunox (Thymopentin) in Asymptomatic, HIV-Infected Patients Receiving Either No, Mono- (AZT,ddl,D4T), or Combination (AZT/ddl, AZT/ddC, AZT/3TC, Proteases) Antiretroviral Therapy, 1993-1996, completed.
9. Open-Label Treatment of HIV-Infected Subjects with Timunox (Thymopentin), 1994-1996, completed.
10. A Randomized, Controlled Multicenter Trial of Filgrastim (rh-GCSF) for the Prevention of Grade 4 Neutropenia in Patients with HIV Infection, 1994-1996, completed.

11. A Phase II Multicenter, Double-Blind, Placebo Controlled Study of Nevirapine Alone or in Combination with Zidovudine in HIV-Infected Asymptomatic Individuals, 1995-1995, completed.
12. A Phase III Safety and Efficacy Trial of Ritonavir plus Current Therapy vs. Placebo in HIV Infected Individuals, 1995-1996, completed.
13. A Phase III Ritonavir Long-Term Treatment Trial, 1996-1998, completed.
14. An Open-Label, Multicenter Study to Provide Expanded Access to and to Obtain Additional Safety Data on Serostim (mammalian-derived recombinant human growth hormone, r-hGH[m]) in the Treatment of Adults with Advanced AIDS Wasting, 1995-1996, completed.
15. Treatment IND Program for Relapsing CMV Retinitis, 1995-1996, completed.
16. Vistide (Cidofovir Injection) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in combination with Intravenous Ara-C in a Patient with AIDS (Treatment IND), 1996-1997, completed.
17. Emergency IND to Perform a Clinical Trial to Determine the Safety and Efficacy of Peptide T in the Treatment of Patients with Progressive Multifocal Leukoencephalopathy (PML), 1996, completed.
18. Open-Label, Non-Comparative Trial of Itraconazole Oral Solution for the Treatment of Patients with Oropharyngeal/Esophageal Candidiasis Nonresponsive to Fluconazole, December 1994-November 1996, completed.
19. Use of DOX-SL (Stealth Liposomal Doxorubicin HCl) in the Treatment of Moderate to Severe AIDS Related Kaposi's Sarcoma, 1994-1996, completed.
20. The Effect of Procrit on the Quality of Life of HIV Infected Patients, 1995-1996, completed.
21. A Multicenter Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate (Crixivan), 800mg q8h versus 1200mg q12h, in HIV-Infected Individuals Having Plasma Viral RNA Less Than 400 copies/ml, on Concomitant Therapy with 2 Nucleoside Analog Reverse Transcriptase Inhibitors (NRTI), 1998-2000, completed.
22. A Phase III, Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens (DMP266+AZT+3TC, DMP266+Indinavir, Indinavir+AZT+ 3TC) in HIV-Infected Patients, DMP266-006, 1997-2000, completed.
23. A Phase II Stratified, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination with AZT, 3TC, or D4T for the Treatment of Therapy-Naive HIV-Infected Individuals with CD4 Cell Counts >100 Cells/mm³ and HIV-1 RNA Copy Numbers >5,000 copies/mm³, 1997-1999, completed.
24. A Phase II Stratified, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Adefovir Dipivoxil at Two Dose Levels in Triple Combination Therapies with Protease Inhibitors (Saquinavir and/or Nelfinavir) and Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-Infected Patients with CD4 Cell Counts >100 cells/mm³ and HIV-1 RNA Copy numbers >5,000 copies/mm³, and Prior RTI Therapy but no Prior PI Therapy, 1997-1999, completed.
25. 1592/Abacavir Expanded Access Study for HIV/AIDS Patients Failing HAART, Southern New England Geographic Study Site, 1998, completed.
26. An Open-Label Study to Evaluate the safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who are Intolerant

- (Hyperlipidemia with or without Lipodystrophy) but not Failing their Current Protease Inhibitor Therapy, PRO30012, 1998-1999, completed.
27. A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naïve HIV-1 Infected Patients, FTC-301, 2000-2003, completed.
 28. ABT-378/r Early Access Program For HIV+ Patients Failing and/or Intolerant to Available Antiretroviral Agents, Protocol M99-046, 2000, completed.
 29. Genotype Assisted Initial Nelfinavir Study (GAIN), AG1343-1205, 2000-2002, completed.
 30. The Vigilance II Study: The Use of Genotyping in HIV-1 Therapy, Protocol 100-99004, 2000-2002, completed.
 31. A Phase IV, Open-Label Study to Assess the Safety and Tolerability of Abacavir (Ziagen) in HIV-1 Infected Individuals and Investigate the Effect of Baseline Genotype with Virtual Phenotype on the Response to Abacavir (Ziagen) in Therapy Experienced Subjects in the Clinical Setting, Protocol ESS40009, 2000, completed.
 32. A Randomized, Double-Blind, Adjuvant-Controlled, Multicenter Study to Compare the Virologic and Immunologic Effect of Highly Active Antiretroviral Therapy (HAART) Plus Remune Versus HAART Plus Incomplete Freund's Adjuvant (IFA) in Antiretroviral-Naïve Patients Infected with Human Immunodeficiency Virus Type 1 (HIV-1), Protocol AG1661-202, 2000-2001, completed.
 33. A Phase I/II Study of the Safety and Antiretroviral Activity of Nine Hydroxyurea Regimens in Combination with ddI and d4T, RIGHT702, 1999-2001, completed.
 34. A Phase II Multi-Center Trial Using Low Flow, Extracorporeal Whole-Body Hyperthermia (EWBH) in HIV/AIDS Patients Resistant to Antiretroviral Therapies, 1999-2001, completed.
 35. Resensitization and Salvage Treatment of HIV Infected Patients Failing HAART by Ampligen Intervention, Protocol AMP719, 2001-2003, completed.
 36. The Safety and Efficacy of Ampligen during Structured Treatment Interruptions in Healthy HIV-Infected Patients with Controlled Viremia, Protocol AMP720, 2001-present, ongoing.
 37. RESIST 1 (BI 1182.12): Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients with Tipranavir (BI 1182.12), 2003-ongoing.
 38. BI 1182.51: Dual Boosted-PI PK trial: An Open-Label, Randomised, Parallel Group Pharmacokinetics Trial of Tipranavir/Ritonavir (TPV/RTV), Alone or in Combination with RTV-Boosted Saquinavir (SQV), Amprenavir (APV) or Lopinavir (LPV), Plus an Optimized Background Regimen, in Multiple Antiretroviral (ARV) Experienced HIV-1 Patients, 2003-2005, completed.
 39. BI 1182.17: A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects, 2004-2005, completed..
 40. TMC125-223: A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125 in HIV-1 Infected Subjects with Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and with at Least Three Primary PI Mutations, 2004-2005, completed.
 41. TMC125-211: An Open-Label Trial of TMC125 in HIV-1 Infected Subjects Who Were Randomized to an Active Control Arm of Any Sponsor Selected TMC125 Trial and Either Virologically Failed or Completed the Entire Treatment Period, 2004-ongoing.

42. TMC125-229: An Open-Label Trial With TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor Selected TMC125 Trial and Were Treated for at Least 48 Weeks, 2005-ongoing.
43. HARS24380: A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS, 2004-2005, completed.
44. P02095: Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections, 2005-ongoing.
45. CCR104627: A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-Tropic and R5/X4-Tropic HIV-1 Infected, Treatment-Experienced Subjects with Drug-Resistant Virus or an Observational Study, 2005, completed.
46. CCR102709: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination with a Ritonavir-Containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks, 2005, completed.
47. CCR104458: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination with a Ritonavir-Containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks, 2005, completed.
48. A Phase IIIb, Open -Label, Randomized Multi-Center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, in Combination with Two Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in HIV-1 Infected Subjects Experiencing Their First Virologic Failure While Receiving a NNRTI-Containing HAART Regimen, 2004-ongoing.
49. A Phase IV, Multicenter, Cross-Sectional Study to Evaluate the I50L Substitution Among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV), 2004-ongoing.
50. MOTIVATE (A4001028): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427, 857, in Combination with Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects, 2005-ongoing.
51. HEAT: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 96-Week Trial Comparing Epzicom to Truvada in Combination with Kaletra in Antiretroviral-Naïve HIV-1 Infected Subjects, 2005-ongoing.

MEDICAL PUBLICATIONS/ABSTRACTS

1. Lord JT, Ziboh VA, Blick G, et al. The Effects of Photosensitizing Antibiotics and Ultraviolet Irradiation on the Biosynthesis of Prostaglandins. British Journal of Dermatology, 1978;98(1):31-38.
2. Ziboh VA, Lord JT, Blick G, et al. Alteration of Prostaglandin Biosynthesis in Rat Chloroleukemic Tumor. Cancer Research, 1978;37(11):3794-3780.
3. Blick G, Padilla AJ, Altmeyer VA, et al. Recurrent Hyperinsulinemic Hypoglycemia, Psychosis, and Flushing in a 75-year old Man. Connecticut Medicine, 1988;52(1):16.
4. Blick G, Camp WA, Morris D, et al. Improving the Outcome of Subarachnoid Hemorrhage using Morphine and Phenobarbital Therapy. Connecticut Medicine. 1988;52(1):19.
5. Blick G, et al. Active Immunization of recombinant GP160/P24 Vaccine in HIV-Infected Individuals: A Community-Based Phase I/II
6. Trial of Toxicity and Immunogenicity. Seventh International Conference on AIDS, Florence, Italy, June 16-21, 1991, abstract MA 1343.
7. Blick G, et al. A Phase I/II Study of Toxicity, Immunogenicity, and Efficacy of Intradermal Immunization with Recombinant gp160 and p24 Alum Absorbed Vaccines in HIV-Infected Individuals. ABSTRACTS From the Third International Conference on AIDS Vaccines, Marco Island, FL, October 1991.
8. Blick G, et al. A Phase I/II Study of the Toxicity, Immunogenicity, and Efficacy of Intramuscular Immunization with Recombinant gp160 and p24 Vaccines in HIV-Infected Individuals Regardless of CD4 Cell Count. ABSTRACTS From the Third International Conference on AIDS Vaccines. Marco Island, FL, October 1991.
9. Blick G. New Directions in the Treatment of HIV Infection: Passive Immunotherapy, Plasmapheresis, Thymopentin, and HIV-1 gp160 Vaccine. Journal of Naturopathic Medicine, 1992(3)1:36-40.
10. Blick G, et al. A Phase I/II Study of the Toxicity, Immunogenicity, and Efficacy of recombinant gp160 and p24 Vaccines in HIV-Infected Individuals (12-Month Update), Eighth International Conference on AIDS, Amsterdam, Netherlands, July 19-24, 1992, abstract TuB0562.
11. Blick G, Crook S. Vaccine Theory: GP160 May Effect Immune Response to HIV. Searchlight, 1993(3)1:69.
12. Blick G, Crook S. Therapeutic Use of gp160 Vaccine in HIV-Infected Individuals. HIV Advisor, 1993(7)1:9-11.
13. Blick G, Crook S, Buchanan S, et al. A Phase I/II Trial Evaluating the Combination Use of Recombinant gp160 and p24 Vaccines vs. gp160 Placebo by Intradermal Injection in HIV-Seropositive Individuals Regardless of CD4 Cell Counts. Ninth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, abstract PoB272128.
14. Blick G, Crook S, Buchanan S, et al. A Phase I/II Trial Evaluating the Combination Use of Recombinant gp160 and p24 Vaccines in HIV-Seropositive Individuals Regardless of CD4 Cell Counts. Ninth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, abstract PoB272131.
15. Goldstein G, Conant MA, Beall G, et al. Thymopentin with Zidovudine (AZT) Reduces Disease Progression in Asymptomatic HIV-Infected Patients. Ninth International Conference on AIDS, Berlin, Germany, June 6-11, 1993, abstract PoB28-2144.
16. Blick G, Crook S, Buchanan S. Therapeutic Vaccines in HIV Infection. AIDS Reader. 1993(3)4:114-132.

17. Blick G. 1993 Was a Year of Promise and Dashed Hopes in AIDS Battle. Greenwich Times, Guest Commenter on AIDS, December 1, 1993.
18. Sheppard JD, Blick G, Caldwell PT, et al. Treatment of Ocular Toxoplasmosis with Atovaquone, A Cysticidal Hydroxynaphoquinone. Association for Research in Vision and Ophthalmology (ARVO) Conference, August 1993, poster presentation.
19. Goldstein G, Fisher A, Hirsch R, Hwang CC, Meyerson L. Thymopentin treatment reduces disease progression in asymptomatic HIV infected subjects. Program Abst 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1994 Oct 4-7;62.
20. Goldstein G, Conant M, Beall G, et al. Safety and Efficacy of Thymopentin in Zidovudine (AZT)-Treated Asymptomatic HIV-Infected Subjects with 200-500 CD4 Cells/mm³: A Double-Blind Placebo Controlled Trial. JAIDS 1995(8)3:279-288.
21. Goldstein G, Hirsch RL, Meyerson L, et al. Open Label Thymopentin Reduces Disease Progression in Asymptomatic HIV Subjects Previously on Double-Blind Placebo. Abstracts of the Second National Conference on Human Retroviruses and Related Infections, Washington DC, January 29-February 2, 1995, abstract 513, pl50.
22. Merigan TC, Hirsch RL, Fisher AC, et al. The Prognostic Significance of Serum Viral Load, Codon 215 Reverse Transcriptase Mutation and CD4 TCells on Progression of HIV Disease in a Double-Blind Study of Thymopentin in Asymptomatic HIV Infected Subjects. AIDS 1996(10)2:159-165.
23. Cameron B, Heath-Chiozzi M, Kravci S, et al. Prolongation of Life and Prevention of AIDS in Advanced HIV Immunodeficiency with Ritonavir. Abstracts from the 3rd Conference on Retrovirology and Opportunistic Infections, Washington, DC, Jan. 28-Feb. 1, 1996, Abstract LB6a.
24. Miller G, Rigsby MO, Heston L, et al. Antibodies to Butyrate-inducible Antigens of Kaposi's Sarcoma Associated Herpesvirus in Patients with HIV-1 Infection, acknowledgment. N Engl J Med 1996;(334)20: 1292-1297.
25. Blick G, Crook S, Hopkins U, et al. Passive Immunotherapy in Advanced HIV Infection and Therapeutic Plasmapheresis in Asymptomatic HIV Positive Individuals. Eleventh International Conference on AIDS, Vancouver, Canada, July 7-12, 1996, abstract 2868.
26. Blick G, Garton T, LaGravinese L, et al. Successful Use of Cidofovir in Treating AIDS-Related CMV Retinitis, Encephalitis, and Esophagitis. JAIDS 1997;15:184-5.
27. Blick G, Scott WF, Crook SW, et al. Passive Immunotherapy in Advanced HIV Infection and Therapeutic Plasmapheresis in Asymptomatic HIV Positive Individuals: A Four-Year Clinical Experience. BIO THERAPY 1998;11:7-14.
28. Blick G, Whiteside M, Garton T, et al. Effective Treatment of Progressive Multifocal Leukoencephalopathy (PML) Using Combination Therapy with Cidofovir. Clinical Infectious Diseases 1998;26(January):191-2.
29. Thymopentin Does Not Slow Disease Progression in Zidovudine Experienced Asymptomatic HIV-Infected Patients: Results of a Multicenter Double-Blind Study. Submitted for publication, 1998.
30. Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim (r-metHuG-CSF) Prevents Severe Neutropenia and Reduces Infective Morbidity in Patients with Advanced HIV Infection: Results of a Randomized, Multicenter, Controlled Trial. AIDS 1998;12:65-74.
31. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised Placebo-Controlled Trial of Ritonavir in Advanced HIV-1 Disease. The Advanced HIV Disease Ritonavir Study Group. Lancet, 1998;351(9102):543-9.
32. Winslow D, Myers A, Blick G, et al. A Phase II Stratified, Randomized, Open Label, Multicenter Study of Adefovir Dipivoxil (ADV) and Indinavir (IDV) in Combination with AZT, 3TC, or d4T for the Treatment of Therapy Naive HIV-Infected Patients with CD4 cell

- counts >100 cells/mm³ and HIV-1 RNA copy numbers >5000 copies/ml. 12th International Conference on AIDS, Geneva, Switzerland, June 1998, abstract.
33. Staszewski S, Morales-Ramirez J, Flanagan T, et al. A Phase II, Multicenter, Randomized, Open-label Study to Compare the Antiretroviral Activity and Tolerability of Efavirenz + Indinavir, Versus Efavirenz + Zidovudine + Lamivudine, Versus Indinavir + Zidovudine + Lamivudine at 24 Weeks [DMP 266-006]. 12th International Conference on AIDS, Geneva, Switzerland, June 28-July 3, 1998, abstract.
 34. Blick G. First Successful Treatment for PML JC Virus. Antiviral Agents Bulletin. 1998;11(2):44.
 35. Myers A, Blick G, Shepp D, et al. Randomized Study of Adefovir Dipivoxil (ADV) in Combination with Indinavir (IDV) and Reverse Transcriptase Inhibitors for Treatment-Naïve HIV-Infected Patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 24-27, 1998, Abstract I-107.
 36. Morales-Ramirez J, Tashima K, Hardy D, et al. A phase III, Multicenter, Randomized, Open-label Study to Compare the Antiretroviral Activity and Tolerability of Efavirenz (EFV) + Indinavir (IDV), Versus EFV + Zidovudine (ZDV) + Lamivudine (3TC), Versus IDV + ZDV + 3TC at 36 weeks. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego CA, September 1998, Abstract I-103.
 37. Tashima K, Staszewski S, Stryker R, The Study 006 Investigator Team, et al. A Phase III, Multicenter, Randomized, Open-Label Study to Compare the Antiretroviral Activity and Tolerability of Efavirenz (EFV) + Indinavir (IDV), versus EFV + Zidovudine (ZDV) + Lamivudine (3TC), versus IDV+ZDV+3TC at 48 Weeks (Study DMP266-006). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4, 1999, abstract LB16.
 38. Morales-Ramirez JO, Godofsky EW, Stryker R, The Study 006 Investigator Team, et al. Longer Time-to-Treatment Failure and Durability of Response with Efavirenz+ZDV+3TC: first analysis of full 1266 Patient Cohort from Study 006. 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, June 23-26, 1999, abstract.
 39. Stryker R, Skiest D, Tashima K, Study 006 Investigator Team, et al. Lack of Clinical Lipodystrophy in Patients Receiving SUSTIVA + NRTIs in Study 006. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, CA, June 26-28, 1999, abstract.
 40. Staszewski S, Morales-Ramirez JO, Godofsky EW, the Study 006 Investigator Team, et al. Longer Time-to-Treatment Failure and Durability of Response with Efavirenz+ZDV+3TC: First Analysis of Full 1266 Patient Cohort from Study 006. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, 1999, oral presentation.
 41. Gallant J, Beal J, Myers R, GS-97-417 Study Team, et al. Randomized, Double-Blind Study of Adefovir Dipivoxil (ADV) at Two Dose Levels in Combination with Nucleoside Reverse Transcriptase Inhibitors (NRTI) and Protease Inhibitors (PI) for NRTI-experienced, PI-Naïve Patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, 1999, Abstract 1976.
 42. Greiger P, Garton T, Blick G. The Use of r-HGH (Serostim) in HIV-Associated Wasting Has Limited and Transient Effect on Glucose Levels and No Effect on Hepatic Function in Patients Switched to Protease Sparing Treatment Regimens. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon Portugal, October 23-27, 1999, abstract 802.
 43. Staszewski S, Nelson M, Barros Aguado C, the Study 006 Investigator Team, et al. Efavirenz (EFV) + Zidovudine (ZDV) + Lamivudine (3TC) Provides Superior Long-Term

Antiretroviral Activity and Tolerability versus IDV+ZDV+3TC at 72 Weeks: Results From A Phase III, Multicenter, Randomized, Open-Label Study in 450 Patients (Study DPC 266-006 Initial Cohort). 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon Portugal, October 23-27, 1999, abstract 129.

44. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz Plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults. Study 006 Team. N Engl J Med 1999 Dec 16;341(25): 1865-74.
45. Gallant J, Naeger L, Beal J, The GS-417 Team, et al. Adefovir Dipivoxil (ADV) 60mg and 120mg in Combination Regimens for PI-Naïve Patients. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000, Abstract 528.
46. Blick G, Henry K, Greiger P, et al. Reduction of Hepatitis C Viremia Following Extracorporeal Whole Body Hyperthermia (EWBH) in an Individual Co-Infected with HIV and HCV. 13th International AIDS Conference, Durban, South Africa, July 9-14, 2000, Abstract TuPeB3191.
47. Blick G, Henry K, Greiger P, et al. A Phase II Randomized, Controlled Trial Using Low-Flow Extracorporeal Whole-Body Hyperthermia (EWBH) in HIV/AIDS Patients Resistant to Highly Active Antiretroviral Therapies (HAART). 13th International AIDS Conference, Durban, South Africa, July 9-14, 2000, Abstract TuPeB3192.
48. Greiger P, Blick G, Carey Z, et al. Successful Maintenance of HIV-1 Aviremia After Switching from Protease Inhibitor (PI) Containing to PI Sparing Regimens. 13th International AIDS Conference, Durban, South Africa, July 9-14, 2000, Abstract WePeB4166.
49. Greiger P, Blick G, Garton T, et al. Follow-up Data on the Effects of r-hGH (Serostim) on Glucose Levels and Hepatic Function in AIDS Wasting Patients Switched to Protease Sparing Treatment Regimens. 13th International AIDS Conference, Durban, South Africa, July 9-14, 2000, Abstract ThPeB5061.
50. Blick G, Henry K, Greiger P, et al. Extracorporeal Whole-Body Hyperthermia (EWBH) as Salvage Therapy in HIV/AIDS Patients. 13th International AIDS Conference: Clinical Science Presentations, 2000;1:529-535.
51. Blick G, Greiger-Zanlungo P, Blick S, et al. Zovirax Brand is More Efficacious than Generic Acyclovir for Suppression of recurrent Herpes Simplex Virus Infections in Patients with HIV Infection. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001, Abstract 723.
52. Greiger-Zanlungo P, Blick G, Sharfuddin M, et al. Effects of Protease Inhibitor-Containing HAART on Metabolic Parameters and Liver Function Tests in patients Co-Infected with HIV and Hepatitis C Virus. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001, Abstract 556.
53. Blick G, Greiger-Zanlungo P, Sharfuddin M, et al. Successful maintenance of Low HIV-1 Viremia After Early Vs. Late Switching from Protease Inhibitor-Containing HAART to PI-Sparing HAART Containing Either Nevirapine, Efavirenz, or Abacavir. 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 8-11, 2001, Abstract 422.
54. Saag MS, Levine AM, CHAMPS Study Group, et al. Once-Weekly Epoetin Alfa Increases Hemoglobin and Improves Quality of Life in Anemic HIV+ Patients. 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 27, 2001, Abstract 708.

55. Irigon-Guichandut M, Mitchell WM, Carter WA, Blick G, et al. The Adjuvant Role of Poly I:Poly C₁₂U in Auto-Vaccination Against HIV During STI of HAART. 3rd Meeting on Novel Adjuvants Currently in Human Testing, Annecy France, Jan 6-9, 2002, Abstract.
56. Greiger-Zanlungo P, Blick G, Garton T, et al. Protease Inhibitor-Sparing Regimens Containing Nevirapine, Efavirenz, or Abacavir Achieve Long-Term HIV-1 Aviremia and CD4 Stabilization but Do Not Improve Metabolic Complications. 14th International AIDS Conference, Barcelona, Spain, July 7-12, 2002, Abstract WePeB5901.
57. Lori F, Pollard R, Blick G, et al. A Low Hydroxyurea Dose (600mg Daily) is Found Optimal in a Randomized, Controlled Trial (RIGHT 702). 14th International AIDS Conference, Barcelona, Spain, July 7-12, 2002, Abstract TuPeB4465.
58. Strayer D, Blick G, Mitchell W, et al. A Phase IIB Prospective, Randomized Controlled Study Evaluating the Immunomodulatory Role of Poly I:Poly C₁₂U Against HIV. 14th International AIDS Conference, Barcelona, Spain, July 7-12, 2002, Abstract LbPeB9010.
59. Mitchell W, Blick G, Strayer D, et al. Antiviral Activity of Poly I:Poly C₁₂U as Monotherapy in Early HIV Infection and in Combination with Antiretrovirals (ARV) in Treatment Experienced Patients Failing HAART. 14th International AIDS Conference, Barcelona, Spain, July 7-12, 2002, Abstract LbPeB9011.
60. Saag M, Cahn P, Raffi F, et al. for the FTC301 Study Team. A Randomized, Double-Blind, Multicenter Comparison of Emtricitabine QD to Stavudine BID. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 23-27, 2002, Late-breaker Abstract #3889.
61. Blick G, Strayer D, Mitchell W, et al. A Phase IIB Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Poly I:Poly C₁₂U Against HIV During Structured Treatment Interruption (STI) of HAART. Antiviral Research, 2002;7:44-45.
62. Blick G, Greiger-Zanlungo P, Garton T, et al. Tenofovir May Cause Severe Hypophosphatemia in HIV/AIDS Patients with Prior Adefovir-Induced Renal Tubular Acidosis. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 9-14, 2003, Abstract 718.
63. Greiger-Zanlungo P, Blick G, Arzu Z, Garton T. Stavudine has an Excellent Long-Term Safety and Toxicity Profile When Used as a First-Line Agent Earlier in Disease with Higher Nadir CD4 Cell Counts and Percentages. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France, July 8-11, 2003, Abstract 76.
64. Greiger-Zanlungo P, Blick G, Arzu Z, Garton T. Stavudine has an Excellent Long-Term Safety and Toxicity Profile When Used as a First-Line Agent Earlier in Disease with Higher Nadir CD4 Cell Counts and Percentages. Antiviral Therapy, 2003;8(4):L54.
65. Blick G, Greiger-Zanlungo P, Strayer D, et al. Interim Results of AMP720: A Phase IIB Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Ampligen (Poly I:Poly C₁₂U) Against HIV During STI. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003, Abstract 596.
66. Blick G, Greiger-Zanlungo P, Strayer D, et al. Interim Results of AMP720: A Phase IIB Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Ampligen (Poly I:Poly C₁₂U) Against HIV During STI. Antiviral Therapy, 2003;8(Suppl 1):S347.
67. Mitchell, W.M., Blick,G, Strayer,D, Carter,WA and AMP 720 Investigators. A Phase IIB Prospective, Randomized, Controlled Study Evaluating AMPLIGEN During Structured Treatment Interruption (STI) of HAART in HIV Infection. Antiviral Research, 2003;57:A41.
68. Raffi F, Saag M, Cahn, et al. for the FTC 301 Study Team. A Randomized, Double-Blind, Multicentre Comparison of Emtricitabine QD to Stavudine BID in Treatment-Naïve HIV-Infected Patients. Antiviral Therapy, 2003;8(Suppl 1):S193-4.

69. Blick G, Greiger P, Garton T, et al. Final Results of a Phase II Randomized, Controlled Study of Extracorporeal Whole-Body Hyperthermia (EWBH) as Salvage Therapy for HIV/AIDS Patients with Multi-Drug Resistant (MDR-) HIV. 9th European AIDS Conference (EACS), Warsaw, Poland, October 25-29, 2003, Abstract 7.4/19.
70. Blick G, Greiger P, Garton T, Arzu Z. Stavudine Has an Excellent Long-Term Safety and Toxicity Profile When Used as a First- or Second-Line Agent Earlier in Disease with Higher Nadir CD4 Cell Counts and Percentages. 9th European AIDS Conference (EACS), Warsaw, Poland, October 25-29, 2003, Abstract 9.1/9.
71. Lori F, Pollard R, Whitman L, Blick G, et al. Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency by Preventing a Switch from Cytostatic to Cytotoxic Effects. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004, Abstract TuPeB4494.
72. Greiger-Zanlungo P, Rubin D, Blick G, Garton T. Quadruple Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy with Trizivir[®] (TZV) and Viread[®] (TDF) in HAART-Naïve and HAART-Experienced HIV/AIDS Patients. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004, Abstract TuPeB4513.
73. Walmsley S, Leith J, Katlama C, et al. Pharmacokinetics and Safety of Tipranavir/Ritonavir (TPV/r) Alone or in Combination with Saquinavir SQV), Amprenavir (APV), or Lopinavir (LPV): Interim Analysis of BI1182.51. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004, Oral Presentation, Abstract WeOrB1236.
74. Lisziewicz J, Foli A, Groff A, Blick G, et al. Control of Immune Activation Contributes to HIV Suppression by Hydroxyurea-Didanosine. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004, Abstract WePeB5692.
75. Blick G, Greiger-Zanlungo P, Garton T, et al. Early Use of Stavudine (d4T) with Higher Nadir CD4 Cell Counts and Percentages is Associated with Less Lipoatrophy and Peripheral Neuropathy in HIV/AIDS Patients: A Case for Revising the BHIVA and DHHS Guidelines to Recommend Earlier Initiation of HAART. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004, Abstract WePeB5875.
76. Tashima K, Staszewski S, Nelson M, et al., and the DPC 226-006 Study Team. Durable Viral Suppression on EFV-Based HAART: 168 Weeks of Follow-up. XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004, Abstract TuPeB4547.
77. Saag MS, Cahn P, Rafi, et al., and the FTC-301A Study Team. Efficacy and Safety of Etricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naïve Patients: A Randomized Trial. JAMA 2004 July 14;292(2):180-9.
78. Hicks C for the RESIST-1 Study Team. RESIST-1: A Phase 3, Randomized, Controlled, Open-Label, Multicenter Trial Comparing Tipranavir/Ritonavir (TPV/r) to an Optimized Comparator Protease Inhibitor/r (CPI/r) Regimen in Antiretroviral (ARV)-Experienced Patients: 24-Week Data. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30-November 2, 2004, Oral Presentation, Abstract LB H-1137.
79. Kagan R, Blick G, Heseltine P, et al. Prevalence and Analysis of a Multi-Drug Resistant HIV-1 PR and RT Genotype Associated with Rapid Progression to AIDS in a Large Clinical Database. 14th International Drug Resistance Workshop, Quebec City, Canada, June 7-11, 2005, Abstract 128.
80. Blick G, Greiger-Zanlungo P, Kagan, R, et al. Patient Zero: the Connecticut Source of the Multi-Drug Resistant, Dual-Tropic HIV-1 Strain Found in NYC. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 24-27, 2005, Oral Presentation, Abstract MoOa0101.

81. Blick G, Greiger-Zanlungo P, Dupree D, et al. Tenofovir DF Can Be Used Safely in Combination with Didanosine-EC 250mg: Effects on Lymphocytes, CD4, Viral Load, and GFR. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 24-27, 2005, Abstract TuPe2.3C22.
82. Greiger-Zanlungo P, Blick G, Dupree D, et al. Daily Valacyclovir is Safe and Effective in Reducing Recurrent HSV-1, HSV-2, and VZV in HIV/AIDS Patients. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 24-27, 2005, Oral Presentation, Abstract TuPe1.4C02.
83. Blick G, Greiger-Zanlungo, Stevens R, et al. Renal Safety Profile in HAART Regimens Containing Tenofovir DF. 10th European AIDS Conference/ECAS, Dublin, Ireland, November 17-20, 2005, Abstract PE9.7/5.
84. Pierone G, Drulak M, Arasteh K, et al. A Long-Term Open-Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir (TPV/r) Use in HIV-1-Infected Patients: 1182.17. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 24-27, 2005, Abstract WePe6.2C05.
85. Nadler J, Grossman H, Hicks C, et al. Efficacy and Tolerability of TMC125 in HIV Patients with NNRTI and PI Resistance at 24 weeks: TMC125-223. 10th European AIDS Conference/ECAS, Dublin, Ireland, November 17-20, 2005, Abstract LBPS3/7A.
86. Greiger-Zanlungo, Blick G, Rubin D, et al. Quadruple Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy with Trizivir (TZV) and Viread (TDF) in Naive and Experienced HIV/AIDS Patients: A 30-Month Follow-up. 10th European AIDS Conference/ECAS, Dublin, Ireland, November 17-20, 2005, Abstract PE7.5/9.
87. Greiger-Zanlungo, Smith C, Blick G, et al. Incidence of Vertical Transmission Among HIV+ Women Treated with HAART During Second and Third Trimester of Pregnancy. 10th European AIDS Conference/ECAS, Dublin, Ireland, November 17-20, 2005, Abstract PE14.2/4.
88. Grossman HA, Hicks C, Nadler J, et al. Efficacy and Tolerability of TMC125 in HIV Patients with NNRTI and PI resistance at 24 weeks: TMC125-C223. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC., December 16-19, 2005, Abstract H-416c.
89. Nadler J, Cohen C, Blick G, et al. Efficacy and Tolerability of TMC125 in Patients with HIV-1 Resistance to Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors: 24-Week Analysis of Trial TMC125-C223. Submitted for publication.
90. Blick G, Kagan RM, Coakley E, et al. Clinical History and Phylogenetic Relatedness Identify the Source of Both the Multidrug Resistant (MDR), Dual-Tropic Primary HIV-1 Infection Found in a Patient with Rapid Progression to AIDS and a Second Unique Recombinant MDR Strain in a Chronically-HIV-1-Infected Heavily Antiretroviral-Experienced Patient. Submitted for publication.

UPDATED JANUARY 2006